What is the Wolverine blend? BPC-157 and TB-500

Where the nickname comes from

The term is vendor vocabulary rather than chemistry. It circulated in the research-supply market as shorthand for the BPC-157 and TB-500 pairing and stuck, the way informal names do when a combination is ordered often enough to need a label. No standards body assigned it and no publication uses it.

Because it is a nickname, the same words describe different vials. Some are 5 mg of each; some are 10 mg of each; some vendors use the name for a three-component blend. The only reliable description of what you are buying is the component list and the milligram split, which is why reputable listings state both.

What the 5/5 and 10/10 notation means

A blend labelled 5/5 contains 5 mg of the first component and 5 mg of the second, for 10 mg of peptide in the vial. A 10/10 contains 10 mg of each, for 20 mg total. The numbers are per-component masses, not a ratio and not a total.

Why these two compounds are paired

The pairing is not arbitrary. The two compounds are studied against different mechanisms, which is the stated rationale for combining them rather than doubling one.

The BPC-157 literature is largely rodent work examining tissue models — the research library on this site indexes studies of Achilles tendon transection and gastric models from the late 1990s onward. The thymosin beta-4 literature examines actin sequestration and cell migration, in corneal and dermal models. Those are different experimental questions, and the pairing reflects an assumption that two mechanisms are better than one.

That assumption has not been tested. There is no published research on the combination as a combination, which is a different statement from saying the combination has been shown not to work. It means the experiment has not been run and published.

BPC-157: what the mechanism studies describe

BPC-157 is a 15-residue partial sequence of a protein identified in gastric juice, which is where the name comes from — body protection compound. It is synthesised directly rather than isolated, and the fragment sold is not a molecule that exists on its own in nature.

The mechanistic literature is largely rodent work and converges on vascular effects. Published studies describe upregulation of vascular endothelial growth factor and effects on the nitric oxide system, and propose angiogenesis — the formation of new blood vessels — as the route by which the compound produced the effects measured in those tissue models. Separate work on tendon fibroblasts in culture describes effects on the focal adhesion kinase pathway that governs how cells attach and migrate.

The word describes is doing deliberate work in those sentences. A proposed mechanism explains an observation; it is not itself an observation, and mechanisms proposed in rodent models have a poor record of surviving translation.

TB-500: actin, and why that is the whole mechanism

Thymosin beta-4 has a defined and uncontroversial molecular function: it binds monomeric G-actin and holds it in reserve, which regulates how quickly actin can polymerise into the filaments a cell uses to change shape and move. That is textbook cell biology rather than a proposal, and it is what the actin-binding domain in the sequence exists to do.

Everything else attributed to the compound follows from that one function. Cell migration requires actin remodelling, so a molecule regulating the available actin pool is positioned to affect migration. The published corneal and dermal model studies measure downstream outcomes; the actin sequestration is the step underneath them.

This is a meaningful difference in evidential quality between the two compounds, and it is rarely stated. TB-500's molecular function is established. BPC-157's proposed mechanism is inferred from outcomes in animal models.

The two mechanisms side by side

The row that matters most for handling is the last pair. BPC-157 carries neither methionine nor cysteine, so the two commonest chemical degradation routes are simply absent. TB-500 carries a methionine, and oxidation adds 16 daltons that typically appears as a shoulder on the main HPLC peak rather than a separate one. In a blend the two share a vial and therefore share storage conditions, which means the whole vial has to be handled to the standard of its most fragile component.

Why the pairing is argued for, and what that argument rests on

The stated case for combining them is that the two mechanisms are complementary rather than redundant: one described as affecting the vascular supply and signalling environment, the other as regulating the cytoskeletal machinery cells use to move. Two different levers rather than two pulls on the same one.

That is a coherent argument and it is entirely theoretical. No published study has tested the combination against either component alone, so the proposition that the pairing outperforms one compound remains an inference from mechanism rather than a finding. Combining two compounds also combines their uncertainties, and a blend has strictly less direct evidence behind it than its components have individually.

Why a blend has no CAS number

A CAS Registry Number identifies a single distinct substance. A mixture of two peptides is not one substance, so it has no number of its own — only its components do: 137525-51-0 for BPC-157 and 77591-33-4 for TB-500.

The same applies to molecular weight. A blend has no single mass, which means the mass-spectrometry identity check that works for a single peptide must be run against each component separately. A blend COA reporting one mass has not identified the contents.

What the BPC-157 and TB-500 literature covers

Both compounds have preclinical literature and neither has completed a Phase III human trial. The studies indexed in the research library below are the primary sources for each component individually. Reading them is the only way to know what was actually measured, in what species, and by what route — details that are routinely lost when the work is summarised second-hand.

What the safety record says about these two

This section reports what the published record contains. The most important thing it contains is very little.

• ◆Neither compound has completed a Phase III human trial.
• ◆For injectable BPC-157, formal Phase I human safety trials with dose escalation and comprehensive monitoring are absent from the published literature.
• ◆Adverse-event profiles that circulate are assembled from animal studies, small trials, and self-reported community data rather than controlled clinical investigation.
• ◆The adverse effects most commonly described in that material are mild gastrointestinal symptoms and local injection-site reactions where a parenteral route was used.
• ◆No controlled human interaction study of the two compounds together exists, so any claim about combined safety — favourable or unfavourable — is speculation rather than a finding.

The dosing question, answered plainly

This is the most-searched question about this blend, so it is worth addressing plainly rather than pretending nobody asks it.

We do not publish a self-administration amount. Not as a hedge — these compounds have no approved human use, no established human dosing, and for injectable BPC-157 no completed dose-escalation study in humans to derive one from. A number published here would be manufactured rather than sourced, and there is no honest way to present a manufactured number.

What the question actually turns on, and what a researcher can determine: the published studies each state what was administered, to which species, by which route, and over what period. Those parameters are in the papers linked below. They describe animal models in almost every case, and rodent parameters do not transfer to other species by simple scaling — allometric conversion is its own methodology with its own literature and its own error bars.

The arithmetic of turning any target amount into a volume is a separate and entirely tractable question, covered in the concentration and volume guide linked below. That guide does the maths without supplying the input, because the input is yours to determine and ours to stay out of.

Blend or two separate vials?

The blend is a convenience format. It trades control for one less reconstitution, which is a reasonable trade when the ratio suits the work and a poor one when it does not. Separate vials cost more handling and give back every degree of freedom the blend removes.

How to verify what you received

• ◆Both component masses stated separately on the label, not just a total.
• ◆A COA showing purity for each component rather than one blended figure.
• ◆Mass spectrometry confirming both molecular weights — 1419.55 and roughly 4963 g/mol.
• ◆A chromatogram with resolved, identified peaks for each component.
• ◆A lot number matching the vial, signed by a laboratory that did not sell it to you.

If the components co-elute, per-component purity cannot be read from that run at all. A blend COA that shows clean separation is evidence the analytical method was developed for this mixture rather than borrowed from a single-compound assay.